dc.contributor.author | Valladares-Garrido, v | es_ES |
dc.contributor.author | Zeña-Ñañez, Sandra | es_ES |
dc.contributor.author | Peralta, C Ichiro | es_ES |
dc.contributor.author | Puicón-Suárez, Jacqueline B | es_ES |
dc.contributor.author | Díaz-Vélez, Cristian | es_ES |
dc.contributor.author | Failoc-Rojas, Virgilio E | es_ES |
dc.date.accessioned | 2022-10-24T13:34:53Z | |
dc.date.available | 2022-10-24T13:34:53Z | |
dc.date.issued | 2022-05-20 | |
dc.identifier.uri | https://hdl.handle.net/20.500.13053/6904 | |
dc.description.abstract | COVID-19 vaccines have achieved a significant reduction in mortality, yet objective estimates are needed in specific settings. We aimed to determine the effectiveness of COVID-19 vaccination at a referral hospital in Lambayeque, Peru. We conducted a retrospective cohort study from February to September 2021. We included hospitalized patients with COVID-19, whose data were stored in NotiWeb, a patient data system of the Peruvian Ministry of Health. We applied a propensity score-weighting method according to baseline characteristics of patients, and estimated hazard ratios (HR) using Cox regression models. Of 1553 participants, the average age was 55 years (SD: 16.8), 907 (58%) were male, and 592 (38%) deceased at 28-day follow-up. Before hospital admission, 74 (4.8%) had been immunized with at least one vaccine dose. Effectiveness against death in vaccinated patients was 50% at 90-day follow-up (weighted HR 0.50, 95% CI 0.28-0.89). Our results support the effectiveness of COVID-19 vaccination against death and provide information after early immunization in Peru. | es_ES |
dc.format | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.subject | COVID-19; Peru; mortality; vaccination; vaccine effectiveness. | es_ES |
dc.title | COVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | https://doi.org/10.3390/vaccines10050812 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.publisher.country | GB | es_ES |
dc.subject.ocde | http://purl.org/pe-repo/ocde/ford#3.03.00 | es_ES |